Sunlight Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 6.5/10
Best for: compounded semaglutide at $299/month
Sunlight's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
then $299/mo ongoing
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
Advertised rates are $159/month on compounded semaglutide, $239/month on compounded tirzepatide, but both are first-month rates; confirm the steady-state price at intake. A single flat monthly rate bundles free shipping and unlimited telehealth visits. Sunlight is LegitScript-certified and calls itself a cost-disrupting alternative to branded GLP-1s, which it describes as high-priced.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Sunlight
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Sunlight at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $159/mo (Site price card shows $299 struck through to $159 first month ('Get $140 Off Today'); FAQ: 'semaglutide starts at $15...)
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How Sunlight scores
Six columns, each one computed from something Sunlight has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
2.5/10$379/month is 42% above the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
6.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Sunlight
Last checked June 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with Sunlight involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Sunlight publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Sunlight does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $299, tirzepatide $379. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether Sunlight serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Sunlight support, as documented
- Phone
- 1-877-378-7008
GLP-1 medications Sunlight offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Peptides Sunlight offers
Sunlight sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Pricing
Prices re-verified
Site price card shows $299 struck through to $159 first month ('Get $140 Off Today'); FAQ: 'semaglutide starts at $159 per month... for the first month.'
Site price card shows $379 struck through to $239 first month; FAQ: 'tirzepatide at $239 per month for the first month.'
Check the price yourself before you pay
Every figure here was read off Sunlight's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- Semaglutide at $299 a month, 58% above the $189 register median for the same drug and form
- Tirzepatide at $379 a month, 42% above the $267 register median for the same drug and form
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Sunlight charges
Two numbers matter here and only one of them is the price. $159 is the opening month; $299/month is what Sunlight charges thereafter.
- Compounded semaglutide — $159 first month, then $299/month
- Compounded tirzepatide — $239 first month, then $379/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Discounting the first month does not change the twelve-month total by much.
Direct Meds dispenses semaglutide and tirzepatide from $249/month, which makes it the honest comparison to run before committing here.
What Sunlight dispenses
Sunlight prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
Sunlight publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want the price to stop moving as your dose climbs
- you want a cheap way to find out whether the medication suits you before committing
Our read
Sunlight is a cheap way to start and an ordinary way to continue. Use the $159 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $299/month before you let it renew twice. MangoRx is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
Sunlight's strongest column is the clinical side — which molecules it will prescribe, and how it handles dosing.
Before you pay Sunlight
Starting at $159/month. Check today's price, then book the free consultation.
Where Sunlight is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Sunlight review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Sunlight's current pricing
Plans start at $159/month. The free consultation is where you learn whether you qualify, and what it costs today.